145 related articles for article (PubMed ID: 36602059)
21. Barrett's esophagus: histopathologic definitions and diagnostic criteria.
Mueller J; Werner M; Stolte M
World J Surg; 2004 Feb; 28(2):148-54. PubMed ID: 14727064
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and recognition of early esophageal neoplasia.
Herszényi L; Pregun I; Tulassay Z
Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
[TBL] [Abstract][Full Text] [Related]
23. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus.
Shakhatreh MH; Duan Z; Kramer J; Naik AD; Helm A; Hinojosa-Lindsey M; Chen GJ; El-Serag HB
Am J Gastroenterol; 2014 Dec; 109(12):1862-8; quiz 1861, 1869. PubMed ID: 25331350
[TBL] [Abstract][Full Text] [Related]
24. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
25. New developments in the endoscopic surveillance of Barrett's oesophagus.
Bergman JJ; Tytgat GN
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i38-42. PubMed ID: 15711007
[TBL] [Abstract][Full Text] [Related]
26. Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.
Kamboj AK; Katzka DA; Iyer PG
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):27-41. PubMed ID: 33213798
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
[TBL] [Abstract][Full Text] [Related]
28. [Results of the endoscopic screening program of esophageal and gastric cardia cancers using iodine staining in Feicheng, Shandong Province, from 2006 to 2012].
Liang S; Li K; Gong J; Wang J; Ma H; Wang G
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):549-53. PubMed ID: 26463335
[TBL] [Abstract][Full Text] [Related]
29. Low-grade dysplasia in Barrett's esophagus.
Odze RD; Goldblum JR
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1419-20; author reply 1420. PubMed ID: 17110303
[No Abstract] [Full Text] [Related]
30. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of results of endoscopic screening of esophageal, gastric cardia and gastric cancers in high risk population].
Zhang J; Wang F; Zhang Y; Quan P; Liu S; Sun X; Lu J
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):158-60. PubMed ID: 24796469
[TBL] [Abstract][Full Text] [Related]
32. Barrett's esophagus surveillance: When, how often, does it work?
Katona BW; Falk GW
Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):9-24. PubMed ID: 21112494
[TBL] [Abstract][Full Text] [Related]
33. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.
Hillman LC; Chiragakis L; Clarke AC; Kaushik SP; Kaye GL
J Gastroenterol Hepatol; 2003 May; 18(5):526-33. PubMed ID: 12702044
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
35. Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.
Gatenby P; Bhattacharjee S; Wall C; Caygill C; Watson A
World J Gastroenterol; 2016 Dec; 22(48):10592-10600. PubMed ID: 28082811
[TBL] [Abstract][Full Text] [Related]
36. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
37. Barrett's esophagus: A historical perspective, an update on core practicalities and predictions on future evolutions of management.
Dent J
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():11-30. PubMed ID: 21199510
[TBL] [Abstract][Full Text] [Related]
38. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.
Fritcher EG; Brankley SM; Kipp BR; Voss JS; Campion MB; Morrison LE; Legator MS; Lutzke LS; Wang KK; Sebo TJ; Halling KC
Hum Pathol; 2008 Aug; 39(8):1128-35. PubMed ID: 18602665
[TBL] [Abstract][Full Text] [Related]
39. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
40. [Barrett's esophagus: diagnosis and therapy].
Schmassmann A; Gebbers JO
Praxis (Bern 1994); 2005 May; 94(21):861-8. PubMed ID: 15966485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
